The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generative AI neuromodulation platform that could speed the development of safe, non-invasive ways of treating neurodegenerative and neuropsychiatric disorders. The platform harnesses the power of generative artificial intelligence (AI) to synthesize, on demand, precision sensory stimulation therapies.
Dr. Erwin Böttinger, Director of the Wyss Center, expressed his enthusiasm for the collaboration, stating, “We are delighted to invest in and partner with Dandelion Science. The promise of generative AI as a new therapeutic paradigm for brain disorders is exciting. AI guided neuromodulation is a key focus area for the Wyss Center, to develop smarter therapies for neurologic and mental health disorders by combining artificial intelligence and novel non-invasive neuromodulation techniques targeting deep brain structures. Dandelion’s innovative deeptech approach, robust intellectual property portfolio, and exceptional team make them an ideal partner. We look forward to the transformative impact this technology could have on patients worldwide.”
